search BlueLine Go
Print this Page Print this Issue Send to a Friend Past Issues
Summer 2009

Release of new generics offers savings opportunities

During 2009 and 2010, 25 brand-name drugs are scheduled to become available in their generic form. The introduction of these generics promises to provide substantial out-of-pocket savings for users. Keep in mind that a generic drug contains the same active ingredients in the same dosage form as a brand-name drug. All generic drugs are approved by the federal Food and Drug Administration (FDA) as safe and effective.

Not all brand-name drugs have exact generic equivalents, but there may be effective generic alternatives within the same therapeutic class.

We encourage our members to use generic medications. “Generic alternatives to high-priced branded drugs help increase adherence to prescribed drug therapies and improve health care, while providing value to cost-conscious consumers and businesses,” said John Frick, R.Ph., director, pharmacy initiative for the Blue Cross and Blue Shield Association.1 Our online tool for members, MyBlueServiceSM, includes a shopping tool to compare prescription drug prices from selected pharmacies. This allows members to find the least expensive, convenient location to fill their prescriptions.

The Pharmacy page under the Physicians & Providers section of our website, www.bcbsfl.com, contains BCBSF Medication Guides and updates.

The table below reflects a summary of the generic drugs that have or are scheduled to become available during 2009.

Brand Drug

Generic Name

* 2009 Generic Availability Date:

Used to treat:

Depakote ER

divalproex ER

January

Seizures

Topamax

topiramate

March

Seizures

Casodex

bicalutamide

April

Prostate Cancer

Cellcept

mycophenolate - mofetil

May

Immune System

Seasonique

levonorgestrel - ethinyl
estradiol

May

Contraception

Alphagan P

brimonidine tartrate
ophthalmic

September

Glaucoma

Prandin

repaglinide

September

Diabetes

Acular

ketorolac
tromethamine
ophthalmic

November

Eye Pain

FemHRT

ethinyl estradiol -
norethindrone acetate

November

Hormone Deficiency

Prevacid

lansoprazole

November

Acid Reflux/Heartburn

Sanctura

trospium

November

Overactive Bladder

Valtrex

valacyclovir

December

Infection

Example Cost Savings

Depakote ER

Retail 30 day supply:

$100.85

divalproex ER

Retail 30 day supply:

$75.20

 

Potential Yearly Savings=

$307.80

 

 

Source: MyRxHealth.com

*All dates are subject to change based on FDA approval process and generic manufacturers involved

1 Source: BCBSA April 2009 press release

Author:
Online Editor:
Online Medical Reviewer:
Date Last Reviewed: 5/26/2009
Date Last Modified: 5/26/2009